Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type9 y' I$ Y& c3 S0 h4 ?5 Q
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 $ C" y i& E. M+ r; l0 W
+ Author Affiliations
% u! r( n$ G) N- I3 @3 P( W
. y! Y. m1 N y5 G/ U1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan ) x. ?' O& k. O q3 N
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
' y& k" J6 \. |/ T/ D1 Q$ X3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan s/ _) I' J* V# x6 E
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan ! r1 B- T! g, g$ c
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan 1 ^% L9 s- j+ X
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan ) U: @/ P7 F8 `6 U
7Kinki University School of Medicine, Osaka 589-8511, Japan : ?$ C# i) u( k' d6 m
8Izumi Municipal Hospital, Osaka 594-0071, Japan
) I+ r7 r. ?2 t* t( x% j' a$ ~9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan ( k S$ a. |! y4 R! B
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp . l" H5 p* e- i& X0 h% e, b2 G+ n
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. % x- d d! ?. [' ]; z, R; D0 S3 f
( R& a, J [. {7 | |